Consistent with reduced tumor size the combination treatment also showed higher expression of DNA damage markers (gamma-H2AX and RPA32) and reduced levels of the proliferation marker Ki67 (Appendix Fig. S6L). This evidence concerns the gene MKI67 and neoplasm.